Analysts See Growth Ahead for Vanguard ESG U.S. Stock ETF
In a recent analysis by ETF Channel, we compared the trading prices of holdings within the Vanguard ESG U.S. Stock ETF (Symbol: ESGV) to their expected target prices from analysts. The resulting weighted average implied target price for the ETF stands at $112.43 per unit.
Current Standings and Potential Upside
The ETF is currently trading around $102.46, suggesting that analysts anticipate a potential upside of 9.73%. Key holdings driving this expectation include Sigma Lithium Corp (Symbol: SGML), CRISPR Therapeutics AG (Symbol: CRSP), and MoonLake Immunotherapeutics (Symbol: MLTX). SGML recently traded at $14.61, but analysts target a price of $27.32, representing a significant upside of 87.01%. For CRSP, the recent price of $47.96 has an upside of 70.89% to a target price of $81.96. Similarly, MLTX’s current price of $46.20 has a forecasted target of $74.00, or 60.17% higher. Below is a twelve-month price history chart comparing the stock performance of these companies:
Summary of Analyst Targets
Here’s a table summarizing the current analyst target prices for the ETF and its notable holdings:
Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
---|---|---|---|---|
Vanguard ESG U.S. Stock ETF | ESGV | $102.46 | $112.43 | 9.73% |
Sigma Lithium Corp | SGML | $14.61 | $27.32 | 87.01% |
CRISPR Therapeutics AG | CRSP | $47.96 | $81.96 | 70.89% |
MoonLake Immunotherapeutics | MLTX | $46.20 | $74.00 | 60.17% |
Evaluating Analyst Predictions
Are these analyst targets well-founded or overly optimistic? Investors should consider if analysts have accounted for recent developments in these companies and their industries. A high target price might signal confidence in future growth; however, it could also lead to potential downgrades if the targets become outdated. These are critical questions for investors to explore further.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Funds Holding HTWO
• Funds Holding DLHC
• Top Ten Hedge Funds Holding RGA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.